$0.87
2.72% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Sangamo Therapeutics, Inc. Stock price

$0.87
+0.05 6.02% 1M
+0.24 38.79% 6M
+0.32 59.58% YTD
+0.27 44.67% 1Y
-8.93 91.15% 3Y
-8.32 90.57% 5Y
-10.35 92.27% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.02 2.66%
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Key metrics

Market capitalization $175.84m
Enterprise Value $177.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.43
P/S ratio (TTM) P/S ratio 14.32
P/B ratio (TTM) P/B ratio 7.42
Revenue growth (TTM) Revenue growth -94.38%
Revenue (TTM) Revenue $12.28m
EBIT (operating result TTM) EBIT $-204.28m
Free Cash Flow (TTM) Free Cash Flow $-178.79m
Cash position $27.79m
EPS (TTM) EPS $-1.38
P/E forward negative
P/S forward 4.27
EV/Sales forward 4.30
Short interest 8.68%
Show more

Is Sangamo Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Sangamo Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

4x Buy
50%
4x Hold
50%

Analyst Opinions

8 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Sangamo Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
12 12
94% 94%
100%
- Direct Costs 18 18
24% 24%
143%
-5.32 -5.32
103% 103%
-43%
- Selling and Administrative Expenses 10 10
73% 73%
83%
- Research and Development Expense 171 171
32% 32%
1,394%
-187 -187
116% 116%
-1,520%
- Depreciation and Amortization 18 18
24% 24%
143%
EBIT (Operating Income) EBIT -204 -204
103% 103%
-1,663%
Net Profit -250 -250
26% 26%
-2,033%

In millions USD.

Don't miss a Thing! We will send you all news about Sangamo Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sangamo Therapeutics, Inc. Stock News

Neutral
24/7 Wall Street
3 days ago
Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.
Neutral
Seeking Alpha
about 2 months ago
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants Nicole Germino - Truist Securities Gena ...
Positive
InvestorPlace
about 2 months ago
Sangamo Therapeutics (NASDAQ: SGMO ) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat certain neurodegenerative diseases.
More Sangamo Therapeutics, Inc. News

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Head office United States
CEO Alexander Macrae
Employees 405
Founded 1995
Website www.sangamo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today